Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities Available to Purchase

Tumors mutated in IDH1 tend to have lower levels of the essential substrate NAD⁺. In this issue of Cancer Discovery, Nagashima and colleagues exploit this metabolic sensitivity by devising a combinatorial therapy that both further reduces the pools as well as sequesters the remaining substrate in PAR chains, sensitizing the cells to temozolomide and PARG inhibition.

See related article by Nagashima et al., p. 1672.